Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accuracy, andthe, antitumor, Barrett, bearing, Biofrontera, blockade, borrow, borrowing, BV, carcinoma, carryforward, Celularity, chain, chimeric, China, colorectal, comparison, contractedwith, correlated, creditworthy, curtailed, cytotoxic, cytotoxicity, declared, Delta, Description, detract, disagree, disrupt, driven, durable, easily, easy, eleven, elicit, epidemic, eradicating, escape, exploitation, Ferrara, forecast, formidable, forward, Gamma, geography, GLP, GmbH, halted, heavily, Helmholtz, HMGU, identification, ill, implicit, impractical, inactivating, incorrect, incremental, incurredfor, indefinitely, infection, infusion, inoperable, Institutet, INTASYL, interrupted, intratumorally, John, judgement, Karolinska, launched, legacy, lengthy, lessee, Lifetime, mandating, Mateon, methodology, mice, Molecular, monthsfrom, multinational, NER, noncurrent, nonharmful, novelINTASYL™compound, NV, obviating, ofour, onour, outbreak, pandemic, paused, Pennsylvania, political, pose, prepayment, purity, quarantined, ready, recoverable, replicated, resected, resigned, restrain, retention, RHEI, shut, signatory, spread, Storeroom, strain, stricter, Supplemental, supplier, temporarily, theefficacy, threshold, toprofessional, unduly, unexpectedly, unrest, vaccine, venture, verify, version, Wuhan, Zentrum
Removed:
achieved, adequately, advantage, Advisory, age, aging, agreed, Alexey, ALS, amyotrophic, applied, ascribed, assign, attenuated, automatically, bank, build, capability, carried, clearance, clinically, color, commensurate, commonly, connective, consisting, consumer, converted, CTGF, customary, dedicated, deficiency, degeneration, dermal, diligence, diphenylcyclopropenone, dismutase, dose, dosing, DPCP, dramatically, Eliseev, enzyme, escalating, escalation, estate, expired, expiring, eye, factor, fibrotic, fileno, Gehrig, hair, Hapten, host, HPV, hyperpigmentation, hypertrophic, immunocompromised, immunomodulator, implementation, improvement, inhibition, inhibitor, initiated, initiating, intradermal, intraocular, Juno, killing, length, liver, Lou, macular, melanin, million, minimum, neurodegenerative, Neuropharma, ocular, onForm, ophthalmologic, original, ovarian, overhead, Page, Pamela, papilloma, path, Pavco, pigment, pigmentation, play, prerequisite, preventative, pro, produced, progression, proper, prophylactic, qualitative, quantitative, quoted, rata, real, receivable, recombinant, reducing, rental, representative, retinal, reverting, Samcyprone, scar, scarring, Seller, sensitization, Serono, signature, subjected, subretinal, sum, superoxide, surgical, targeted, Thera, therapeutically, thereto, tied, tolerability, tolerated, tone, topical, transferred, TYR, tyrosinase, undisclosed, unpredictable, unrestricted, utilize, utilizing, validated, visual, wart, weekly, Wolfson
Filing tables
Filing exhibits
PHIO similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Phio Pharmaceuticals Corp.
Marlborough, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (Nos. 333-183633, 333-189521, 333-189522, 333-215870, 333-215871, 333-227013, 333-2350547 and 333-236784) and Form S-3 (No. 333-224031) of Phio Pharmaceuticals Corp. of our report dated March 26, 2020, relating to the consolidated financial statements, which appears in this Form 10-K.
/s/ BDO USA, LLP
Boston, Massachusetts
March 26, 2020